Cargando…
Newer therapies for multiple sclerosis
The newer immunotherapies for multiple sclerosis (fingolimod, natalizumab, dimethyl fumarate, teriflunomide, alemtuzumab) offer advantages of efficacy or tolerability over the injectable therapies of the 1990s. But they also have greater risks. As further treatments emerge (daclizumab and ocrelizuma...
Autor principal: | Coles, Alasdair |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4604695/ https://www.ncbi.nlm.nih.gov/pubmed/26538846 http://dx.doi.org/10.4103/0972-2327.164824 |
Ejemplares similares
-
Safety of Newer Disease Modifying Therapies in Multiple Sclerosis
por: Jalkh, Georges, et al.
Publicado: (2020) -
Promoting remyelination in multiple sclerosis
por: Cunniffe, Nick, et al.
Publicado: (2019) -
Alemtuzumab: evidence for its potential in relapsing—remitting multiple sclerosis
por: Brown, JWL, et al.
Publicado: (2013) -
Newer anabolic therapies in osteopororsis
por: Mittal, Monika, et al.
Publicado: (2012) -
Newer Antibacterials in Therapy and Clinical Trials
por: Paknikar, Simi S, et al.
Publicado: (2012)